Semaglutide

Ozempic · Wegovy · Rybelsus

Rank#999
Weight LossApprovedApprovedPrescriptionSubQOral

Popular for:Weight loss, type 2 diabetes, cardiovascular risk reduction

4357

Total Studies

2525

Human Studies

Approved

Evidence Level

Approved

FDA Status

Overview

Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist developed by Novo Nordisk. It is arguably the most impactful obesity drug ever developed, marketed as Ozempic (type 2 diabetes), Wegovy (obesity), and Rybelsus (oral form for diabetes). It sparked the modern GLP-1 weight loss revolution and is one of the best-selling drugs in history.

**Originally developed for: **Type 2 diabetes glycemic control (Ozempic, FDA approved December 2017). Subsequently developed for chronic weight management (Wegovy, FDA approved June 2021). Now being studied for cardiovascular risk reduction, NASH, Alzheimer's, and addiction.

Mechanism of Action

Semaglutide mimics natural GLP-1 hormone. It binds to GLP-1 receptors in the pancreas (stimulating insulin secretion), gut (slowing gastric emptying), and brain (reducing appetite and food cravings by acting on hypothalamic hunger centers). It has 94% structural homology to native GLP-1 but is modified with a fatty acid chain that binds to albumin, extending its half-life to ~7 days (enabling once-weekly dosing).

Key Research Benefits

Primary Benefits:

Significant weight loss — ~15% average at 2.4 mg (STEP trials, NEJM 2021)
Glycemic control — HbA1c reductions of 1.5-1.8% (SUSTAIN trials)
Cardiovascular risk reduction — SELECT trial: 20% reduction in MACE (heart attack, stroke, CV death) in overweight/obese adults

Secondary/Emerging Benefits:

Kidney protection — FLOW trial showed 24% reduction in kidney disease progression
NASH/MASLD improvement — liver fat reduction in studies
Addiction reduction — emerging research suggests reduced alcohol, nicotine, and other substance cravings
Alzheimer's disease — clinical trials underway

Clinical Evidence Summary

Research Pipeline

Preclinical
Animal
Phase I
Phase II
Phase III
Approved

4357

Total Studies

2525

Human Studies

- STEP trials (1-5) — Phase 3 obesity program. STEP-1 (NEJM, 2021): 14.9% weight loss at 68 weeks with 2.4 mg.

- SUSTAIN trials (1-10) — Phase 3 diabetes program. Comprehensive data on glycemic control.

- SELECT trial (NEJM, 2023) — 17,604 participants. 20% reduction in major adverse cardiovascular events. Led to expanded FDA indication for CV risk reduction.

- FLOW trial — 24% reduction in kidney disease progression. Led to expanded indication for chronic kidney disease.

> Clinical trial status: FDA APPROVED for multiple indications. One of the most extensively studied drugs in recent history with 50,000+ patients in clinical trials. Active research continues for Alzheimer's, NASH, addiction, heart failure, and more.

Key Studies / PubMed References

4,357 studies found on PubMed · showing top 25 by relevance

View all on PubMed

Semaglutide ameliorates cardiac remodeling in male mice by optimizing energy substrate utilization through the Creb5/NR4a1 axis.

Animal Study

Ma YL, Kong CY, Guo Z, et al. · Nature communications · 2024

PMID: 38834564

Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial.

Human Study

Ryan DH, Lingvay I, Deanfield J, et al. · Nature medicine · 2024

PMID: 38740993

Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide.

Human Study

Hathaway JT, Shah MP, Hathaway DB, et al. · JAMA ophthalmology · 2024

PMID: 38958939

A systematic review of the effect of semaglutide on lean mass: insights from clinical trials.

Meta-Analysis

Bikou A, Dermiki-Gkana F, Penteris M, et al. · Expert opinion on pharmacotherapy · 2024

PMID: 38629387

Clinical Pharmacokinetics of Semaglutide: A Systematic Review.

Meta-Analysis

Yang XD, Yang YY · Drug design, development and therapy · 2024

PMID: 38952487

Side Effects & Safety

Common Side Effects:

Nausea (~20-44% in trials, usually decreases over time)
Diarrhea (~15-30%)
Vomiting (~5-24%)
Constipation
Headache, fatigue

Rare but Serious Risks:

Pancreatitis
Thyroid C-cell tumors (boxed warning)
Gallbladder disease
Muscle mass loss without exercise — important to maintain resistance training
"Ozempic face" — facial volume loss from rapid fat loss

> Boxed Warning: Thyroid C-cell tumors in rodents. Contraindicated in MTC/MEN2 history. Not for type 1 diabetes. Caution with pancreatitis history. Important: ~2/3 of weight is regained within 1 year of stopping. Long-term or indefinite use may be necessary.

Known Interactions

No curated interaction entry is live for Semaglutide yet.

Until the interaction table is fully populated, use the interaction checker and related peptides below to explore adjacent compounds and likely research pairings.

Frequently Asked Questions

Research Disclaimer

This page is for research and educational purposes only. The information presented is based on published scientific literature and does not constitute medical advice, diagnosis, or treatment recommendations. Semaglutide is not approved by the FDA for human therapeutic use. Always consult a qualified healthcare professional before making any health-related decisions. The studies referenced are linked to their original PubMed sources for verification.